Ferumoxytol · Feraheme

Other

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Kidney Disease, Iron Deficiency Anemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (19)
Chronic Kidney Disease
NCT01264679 · AMAG Pharmaceuticals, Inc.
2011-12-27 – 2015-04-24 · Iron Deficiency Anemia
What this study did
NCT01155375 · AMAG Pharmaceuticals, Inc.
2011-10-17 – 2014-06-24 · Iron Deficiency Anemia
What this study did
NCT01155388 · AMAG Pharmaceuticals, Inc.
2011-10-17 – 2014-06-24 · Iron Deficiency Anemia, Nondialysis-dependent Chronic Kidney Disease
What this study did
Iron Deficiency Anemia
NCT03893045 · AMAG Pharmaceuticals, Inc.
2019-09-18 – 2026-10 · Iron Deficiency Anemia
What this study did
NCT04268849 · Auerbach Hematology Oncology Associates P C
2020-02-27 – 2026-02 · Iron Deficiency Anemia
What this study did
NCT04253626 · Stanford University
2021-01-21 – 2024-07-01 · Pregnancy Related, Anemia, Iron Deficiency
What this study did
NCT03657433 · University of Arizona
2018-12-17 – 2022-04-01 · Iron Deficiency Anemia of Pregnancy
What this study did
NCT01114217 · AMAG Pharmaceuticals, Inc.
2010-07-27 – 2013-04-23 · Iron Deficiency Anemia
What this study did
Other / comorbidity
NCT07461948 · Jonsson Comprehensive Cancer Center
2025-10-27 – 2028-10-27 · Glioblastoma
What this study did
NCT02954510 · Brigham and Women's Hospital
2017-02-01 – 2024-02-27 · Coronary Artery Disease
What this study did
NCT06348524 · Transmed Solutions
2015-01-01 – 2022-12-30 · Coronary Artery Disease
What this study did
NCT00255450 · AMAG Pharmaceuticals, Inc.
2005-01 – 2006-08 · Anemia
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT02319278 · University of Edinburgh
2014-12 – 2016-11 · Cardiac Transplant, Cardiac Sarcoid, Myocarditis, Healthy Volunteers
What this study did
Phase 2 (17)
Chronic Kidney Disease
NCT01052779 · AMAG Pharmaceuticals, Inc.
2010-03-01 – 2012-04-19 · Iron Deficiency, Anemia, Kidney Disease
What this study did
Iron Deficiency Anemia
NCT05340465 · University of Washington
2022-11-27 – 2027-06-30 · Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
What this study did
NCT02499354 · Auerbach Hematology Oncology Associates P C
2014-08 – 2022-05-31 · Restless Legs Syndrome, Iron Deficiency Anemia
What this study did
Other / comorbidity
NCT03649880 · OHSU Knight Cancer Institute
2019-06-01 – 2030-01-31 · IDH Wild Type Glioblastoma
What this study did
NCT06483061 · University of Alberta
2025-05-01 – 2029-09-01 · Epilepsy, Temporal Lobe
What this study did
NCT03270059 · OHSU Knight Cancer Institute
2017-10-06 – 2028-12-15 · Central Nervous System Neoplasm, Cranial Nerve Disorder, Metastatic Malignant Neoplasm in the Brain
What this study did
NCT07452250 · Min Zhou
2026-03-08 – 2026-08 · Venous Diseases
What this study did
NCT03347617 · OHSU Knight Cancer Institute
2017-12-20 – 2025-06-23 · Glioblastoma
What this study did
NCT01336803 · Heike E Daldrup-Link
2011-08 – 2023-10 · Bone Cancer, Chondrosarcoma, Ewing's Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Bone Necrosis, Bone Sarcoma, Osteomyelitis
What this study did
NCT00659776 · Oregon Health and Science University
2004-07 – 2021-12 · Nervous System Diseases, Diagnostic Imaging
What this study did
NCT03234309 · OHSU Knight Cancer Institute
2017-10-20 – 2021-08-30 · Brain Neoplasm
What this study did
NCT03325166 · OHSU Knight Cancer Institute
2017-11-03 – 2021-03-01 · Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT00659126 · OHSU Knight Cancer Institute
2006-11-16 – 2020-12-31 · Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm
What this study did
NCT00707876 · AMAG Pharmaceuticals, Inc.
2008-09-01 – 2020-08-15 · Peripheral Arterial Disease (PAD)
What this study did
NCT02141490 · National Cancer Institute (NCI)
2014-05-15 – 2018-11-20 · Prostate Cancer, Bladder Cancer, Kidney Cancer
What this study did
NCT02678767 · Beau Nakamoto
2015-02 – 2017-09 · AIDS Dementia Complex
What this study did
NCT01995799 · University of Edinburgh
2013-05-24 – 2015-06-30 · Myocardial Infarction, Inflammation
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT01542879 · Stanford University
2012-02-22 – 2022-08-08 · Cancer
What this study did
NCT02189889 · University of Texas Southwestern Medical Center
2013-04-09 – 2019-07-26 · Anemia, Cardiovascular Disease
What this study did
Phase 1 (29)
Chronic Kidney Disease
NCT05045872 · The First Affiliated Hospital with Nanjing Medical University
2021-09-17 – 2024-09-03 · Chronic Kidney Diseases
What this study did
Other / comorbidity
NCT04369560 · Jodi Maranchie
2025-05-23 – 2028-12-30 · Urinary Bladder Neoplasms
What this study did
NCT06440408 · Children's Hospital of Philadelphia
2024-09-30 – 2028-06 · Pulmonary Vein Stenosis
What this study did
NCT07634640 · University of Florida
2023-11-03 – 2027-05-31 · Heart Failure With Preserved Ejection Fraction (HFPEF)
What this study did
NCT04900792 · Bryan Allen
2023-02-28 – 2026-12-31 · Glioblastoma, Glioblastoma Multiforme
What this study did
NCT03179449 · Michael Iv
2017-07-01 – 2025-06-01 · Childhood Brain Neoplasm
What this study did
NCT03084523 · Yale University
2017-04-26 – 2024-06-03 · Stroke, Intracranial Atherosclerosis
What this study did
NCT05357833 · University of Utah
2022-06-01 – 2023-09-01 · Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
What this study did
NCT02631733 · National Cancer Institute (NCI)
2017-05-31 – 2023-05-24 · Malignant Solid Neoplasm
What this study did
NCT03358563 · University of Wisconsin, Madison
2018-01-17 – 2022-09-02 · Prostate Cancer
What this study did
NCT04776980 · Abramson Cancer Center at Penn Medicine
2022-06 – 2022-06-22 · Glioblastoma Multiforme, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Recurrent, Brain Tumor, Primary
What this study did
NCT03173066 · Brigham and Women's Hospital
2018-09-21 – 2022-05-31 · Pulmonary Embolism
What this study did
NCT04839185 · University of Wisconsin, Madison
2021-04-15 – 2021-10-06 · Fetal Growth Retardation
What this study did
NCT01895829 · M.D. Anderson Cancer Center
2013-09-12 – 2021-09-07 · Head and Neck Cancer
What this study did
NCT03280277 · OHSU Knight Cancer Institute
2018-04-27 – 2021-08-26 · Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7
What this study did
NCT02857218 · OHSU Knight Cancer Institute
2018-04-27 – 2021-08-19 · Stage IIB Esophageal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7, Stage IIIC Esophageal Cancer AJCC v7
What this study did
NCT05959590 · University of New Mexico
2014-02-12 – 2019-08-12 · Osteomyelitis
What this study did
NCT02511028 · National Institute of Neurological Disorders and Stroke (NINDS)
2015-11-27 – 2019-01-29 · Multiple Sclerosis
What this study did
NCT00978562 · OHSU Knight Cancer Institute
2009-08 – 2018-12 · Childhood Brain Neoplasm, Recurrent Childhood Brain Neoplasm
What this study did
NCT02977637 · University of California, Los Angeles
2016-11 – 2018-11 · Hereditary Hemorrhagic Telangiectasia
What this study did
NCT01770353 · Ipsen
2012-11 – 2018-10-02 · Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
What this study did
NCT03678012 · University of Pennsylvania
2018-06-07 – 2018-08-16 · Dental Caries
What this study did
NCT02466828 · Sunnybrook Health Sciences Centre
2015-03 – 2018-04 · Glioblastoma, Hypoxia
What this study did
NCT02452216 · Michael Iv
2015-06-10 – 2017-01-12 · Brain Injury, Central Nervous System Degenerative Disorder, Central Nervous System Infectious Disorder, Central Nervous System Vascular Malformation, Hemorrhagic Cerebrovascular Accident, Ischemic Cerebrovascular Accident, Primary Brain Neoplasm, Brain Cancer, Brain Tumors
What this study did
NCT02689401 · Dana-Farber Cancer Institute
2016-05 – 2016-05 · Esophageal Cancer
What this study did
NCT01296139 · National Cancer Institute (NCI)
2011-01-26 – 2015-03-19 · Prostate Cancer
What this study did
NCT00769093 · OHSU Knight Cancer Institute
2008-10 – 2014-07 · Brain Neoplasms
What this study did
NCT01665846 · University of Hawaii
2011-07 – 2012-06 · HIV Dementia
What this study did
NCT00360425 · AMAG Pharmaceuticals, Inc.
2006-05 – 2006-08 · Anemia
What this study did
Phase 4 (11)
Chronic Kidney Disease
NCT01227616 · AMAG Pharmaceuticals, Inc.
2013-08 – 2017-02 · Iron Deficiency Anemia Treatment, Chronic Kidney Disease(CKD)
What this study did
NCT01942460 · Georges Ouellet
2013-09 – 2014-06 · Iron-Deficiency Anemia, Inflammation, Oxidative Stress
What this study did
Iron Deficiency Anemia
NCT04278651 · Thomas Jefferson University
2021-09-29 – 2026-12-30 · Pregnancy Related, Anemia, Iron Deficiency, Anemia of Pregnancy
What this study did
NCT01148745 · Dialysis Clinic, Inc.
2010-03 – 2010-05 · Iron Deficiency Anemia
What this study did
Other / comorbidity
NCT05515874 · Northwestern University
2020-09-01 – 2025-06-30 · Intracranial Atherosclerosis
What this study did
NCT04205266 · Thomas Jefferson University
2020-02-14 – 2025-01 · Anemia, Iron Deficiency, Heavy Menstrual Bleeding
What this study did
NCT02893293 · Stanford University
2015-05 – 2023-10-31 · Osteonecrosis
What this study did
NCT06110494 · University of Pennsylvania
2020-07-13 – 2022-03-10 · Apical Periodontitis, Pulp Disease, Dental
What this study did
NCT04080908 · NYU Langone Health
2020-01-15 – 2021-10-19 · Anemia
What this study did
NCT02752191 · Paul Finn
2016-04 – 2018-12-19 · Pediatric Congenital Heart Disease
What this study did
Early phase / not applicable (15)
Iron Deficiency Anemia
NCT03777514 · Johns Hopkins University
2019-08 – 2022-09 · IDA in the Post-bariatric Surgical Patient
What this study did
NCT01374919 · Auerbach Hematology Oncology Associates P C
2011-06 – 2012-03 · Iron Deficiency Anemia
What this study did
Other / comorbidity
NCT02070705 · OHSU Knight Cancer Institute
2014-01-31 – 2024-08-07 · Familial Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm
What this study did
NCT02359097 · OHSU Knight Cancer Institute
2015-01-06 – 2021-03-12 · Glioblastoma
What this study did
NCT01815333 · M.D. Anderson Cancer Center
2013-07 – 2019-07-25 · Cancer of Lymph Node
What this study did
NCT02549898 · Danish Headache Center
2015-08 – 2018-06 · Migraine Headache, Migraine Without Aura
What this study did
NCT02253602 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2014-09 – 2018-05 · Esophageal Neoplasms
What this study did
NCT02084303 · Dartmouth-Hitchcock Medical Center
2014-03 – 2018-03-02 · Epilepsy
What this study did
NCT02006108 · Stanford University
2012-11-27 – 2017-04-11 · Renal Transplant Rejection
What this study did
NCT01663090 · Dana-Farber Cancer Institute
2012-09 – 2016-11 · Soft Tissue Sarcoma
What this study did
NCT00103038 · OHSU Knight Cancer Institute
2004-06-04 – 2016-06-10 · Central Nervous System Lymphoma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
What this study did
NCT01983371 · Scott Potenta, MD, PhD
2013-12 – 2016-06 · Colorectal Cancer
What this study did
NCT01927887 · Massachusetts General Hospital
2012-07 – 2016-04 · Papillary Carcinoma of Thyroid Gland, Metastatic Medullary Thyroid Cancer, Follicular Thyroid Cancer Lymph Node Metastasis
What this study did
NCT00660543 · OHSU Knight Cancer Institute
2006-12 – 2014-06 · Adult Brain Glioblastoma
What this study did
NCT01323296 · University of Edinburgh
2010-11 – 2012-10 · Myocardial Infarction
What this study did

Competitive landscape

This drug's own stage for Chronic Kidney Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ferumoxytol (Feraheme): this drugApprovedNanoparticleIV iron replacement therapyPartial signal
NCT00255424: Primary endpoint (hemoglobin change at day 35): ferumoxytol +0.82 ± 1.24 g/dl vs oral iron +0.16 ± 1.02 g/dl, P<0.0001, in favor of ferumoxytol. CT.gov's own citation list ties this Spinowitz 2008 publication specifically to NCT00255424 (not its twin trial NCT00255437).
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Reliable signal
NCT03436693: Incidence of 30% eGFR decline at week 104: 18.2% canagliflozin vs 29.5% placebo; intergroup difference (placebo-canagliflozin) 11.3% (95% CI 1.2-21.5, P=0.029)
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Reliable signal
NCT03036150: Primary composite outcome (sustained eGFR decline >=50%, end-stage kidney disease, or renal/cardiovascular death) at median 2.4 years: 9.2% (197/2152) with dapagliflozin vs 14.5% (312/2152) with placebo; hazard ratio 0.61 (95% CI 0.51-0.72), P<0.001
Difelikefalin (Korsuva)ApprovedPeptideKappa-opioid receptor (agonist, peripherally restricted)Reliable signal
NCT03636269: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12 (Week 12): CR845 0.5mcg/kg 54% (95% CI 43.9 to 63.9) vs Placebo 42.2% (95% CI 32.5 to 52.5)
NCT03422653: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12 (Week 12): CR845 0.5mcg/kg 51% (95% CI 42.9 to 58.9) vs Placebo 27.6% (95% CI 20.2 to 36.6)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT03594110: Primary 1, kidney disease progression or cardiovascular death in the active trial (median 2.0 years): 432/3304 (13.1%) empagliflozin vs 558/3305 (16.9%) placebo; HR 0.72 (95% CI 0.64 to 0.82; P<0.001), met. Primary 2, the same outcome over the active trial plus post-trial follow-up: 865/3304 (26.2%) vs 1001/3305 (30.3%); HR 0.79 (95% CI 0.72 to 0.87), met.
NCT05373680: Adjusted mean difference in eGFR decline vs standard-of-care control: metformin +8.91 ± 1.92 (p<0.001); empagliflozin +5.1 ± 1.89 (p=0.03) — both halted CKD progression vs control.
Etelcalcetide (Parsabiv)ApprovedPeptideCalcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cellsPartial signal
NCT01785849: Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase (Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).): Etelcalcetide 74% vs Placebo 8.3%
NCT01788046: Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase (Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).): Etelcalcetide 75.3% vs Placebo 9.6%
Extended-Release Calcifediol (Rayaldee)ApprovedSmall moleculeVitamin D receptor (VDR), via conversion to calcitriolPartial signal
NCT01704079: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline (Approximately 6 months): CTAP101 30 μg Capsules 49/144 (34.0%) vs Sugar Pill to CTAP101 30 μg 5/72 (6.9%)
NCT01651000: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values (Approximately 6 months): CTAP101 30 μg Capsules 46/141 (32.6%) vs Sugar Pill to CTAP101 30 μg Capsule 6/72 (8.3%)
Ferric Carboxymaltose (Injectafer / Ferinject)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT00317239: Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL (anytime during the study): Ferric Carboxymaltose (FCM) 87/144 vs Ferrous Sulfate Tablets 35/101
Ferric Derisomaltose (Monoferric / Monofer)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT02940860: Change in Hemoglobin (Hb) From Baseline to Week 8 (Baseline to week 8): Iron Isomaltoside/Ferric Derisomaltose 1.22 g/dL (95% CI 1.14 to 1.31) vs Iron Sucrose 1.14 g/dL (95% CI 1.03 to 1.26)
NCT01102413: Change in Hemoglobin (Hb) Concentration From Baseline to Week 4. (Baseline, 4 weeks): Monofer 0.57 g/dL (range -3.1 to 4) vs Iron Sulphate 0.35 g/dL (range -3.7 to 3.9)
Ferric Pyrophosphate Citrate (Triferic)
ApprovedUS marketing discontinued
Small moleculeIron-replacement therapy delivered via dialysateWeak signalNo reviewed efficacy summary in this indication
Finerenone (Kerendia)ApprovedSmall moleculeMineralocorticoid receptorReliable signal
NCT05047263: Total eGFR slope, baseline to month 32 (FIND-CKD): -3.3 mL/min/1.73m2/year finerenone vs -4.0 mL/min/1.73m2/year placebo; between-group difference 0.7 mL/min/1.73m2/year (95% CI 0.3-1.1; p<0.001)
NCT02540993: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death (From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months): Finerenone 504/2833 vs Placebo 600/2841
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
Sucroferric Oxyhydroxide (Velphoro)ApprovedSmall moleculeDietary phosphatePartial signal
NCT03644264: Change in serum phosphorus from baseline to week 12: -0.71 (0.60) mmol/L with sucroferric oxyhydroxide vs -0.63 (0.52) mmol/L with sevelamer; difference in least squares means 0.08 mmol/L (95% CI -0.02, 0.18), meeting the pre-specified non-inferiority margin of -0.34 mmol/L
NCT01464190: Change From Baseline and Levels at Each Time Point for Serum Phosphorus (Every 4 weeks from baseline to Week 28): PA21 — Change from Baseline to Week 4 (n = 346, 236): -0.2 mg/dL (Standard Deviation 1.33); Change from Baseline to Week 8 (n = 325, 238): -0.2 mg/dL (Standard Deviation 1.38); Change from Baseline to Week 12 (n = 322, 242): 0 mg/dL (Standard Deviation 1.43); Change from Baseline to Week 16 (n = 313, 228): 0 mg/dL (Standard Deviation 1.57); Change from Baseline to Week 20 (n = 300, 221): 0 mg/dL (Standard Deviation 1.46); Change from Baseline to Week 24 (n = 286, 208): 0.1 mg/dL (Standard Deviation 1.53); Chnage from Baseline to Week 28 (n = 287, 210): 0.2 mg/dL (Standard Deviation 1.52); Change from Baseline to Endpoint (n = 384, 260): 0.1 mg/dL (Standard Deviation 1.62) vs Sevelamer Carbonate — Change from Baseline to Week 4 (n = 346, 236): -0.1 mg/dL (Standard Deviation 1.47); Change from Baseline to Week 8 (n = 325, 238): 0.1 mg/dL (Standard Deviation 1.56); Change from Baseline to Week 12 (n = 322, 242): 0.2 mg/dL (Standard Deviation 1.55); Change from Baseline to Week 16 (n = 313, 228): 0.2 mg/dL (Standard Deviation 1.75); Change from Baseline to Week 20 (n = 300, 221): 0.1 mg/dL (Standard Deviation 1.44); Change from Baseline to Week 24 (n = 286, 208): 0.2 mg/dL (Standard Deviation 1.78); Chnage from Baseline to Week 28 (n = 287, 210): 0.2 mg/dL (Standard Deviation 1.76); Change from Baseline to Endpoint (n = 384, 260): 0.3 mg/dL (Standard Deviation 1.79)
Taurolidine / Heparin (Defencath / Neutrolin)ApprovedSmall moleculeAntimicrobial/antithrombotic catheter lock solutionReliable signal
NCT02651428: Presence of a CAC-Adjudicated Catheter-Related Bloodstream Infection (CRBSI) in Subjects Receiving Hemodialysis for the Treatment of End Stage Renal Disease (ESRD): Final Analysis (The event time was the number of days from randomization until the occurrence of a CAC-Adjudicated CRBSI or until the subject was censored. The mean participant duration of exposure to study drug was 174 days (range 4-884 days).): Neutrolin Arm 9/397 vs Heparin Arm 32/398
Tenapanor (Xphozah)ApprovedSmall moleculeNHE3 (sodium/hydrogen exchanger isoform 3)Partial signal
NCT03427125: Change in Serum Phosphorus Levels During Placebo Controlled Randomized Withdrawal Period in the Responder Population (12 weeks (randomized withdrawal period)): Tenapanor 10 mg, 20 mg, 30 mg BID 0.43 mg/dL (Standard Deviation 0.199) | Placebo 1.8 mg/dL (Standard Deviation 0.196)
NCT02675998: Primary 4-week randomized-withdrawal serum phosphate change: pooled tenapanor 1.4 mg/dL vs placebo 0.6 mg/dL (p=0.01).
Vadadustat (Vafseo)ApprovedSmall moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT02680574: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36): Vadadustat 0.41 Grams per deciliter (g/dL) (Standard Error 0.036) vs Darbepoetin Alfa 0.42 Grams per deciliter (g/dL) (Standard Error 0.037)
NCT02648347: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36): Vadadustat 1.43 g/dL (Standard Error 0.046) vs Darbepoetin Alfa 1.38 g/dL (Standard Error 0.047)
AND017Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signalNo reviewed efficacy summary in this indication
Anrikefon (HSK21542)Phase 3PeptideKappa-opioid receptor (agonist, peripherally restricted)Reliable signal
NCT05135390: Proportion with ≥4-point WI-NRS improvement at week 12: anrikefon 37% vs placebo 15% (P<0.001)
AP301 (fiber-Iron Phosphate Binder)Phase 3Small moleculeIron-based intestinal phosphate binderPartial signal
NCT07030595: Primary 1, serum phosphate change baseline to week 12, AP301 vs sevelamer carbonate (non-inferiority, margin 0.19 mmol/L): LSM difference -0.02 mmol/L (95% CI -0.10 to 0.06), upper bound below margin, met. Primary 2, serum phosphate change week 24 to week 27, AP301 maintenance dose vs low dose: LSM difference -0.58 mmol/L (95% CI -0.69 to -0.47; P<0.001), equivalent to -1.8 mg/dL, met.
ApecotrepPhase 3Small moleculeTRPC6 (transient receptor potential cation channel subfamily C member 6)Partial signal
NCT05213624: Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12 (At baseline and Week 12.): BI 764198 20 mg 48.9 Predicted percentage of patients (95% CI 29.2 to 68.6) | BI 764198 40 mg 16 Predicted percentage of patients (95% CI -1.5 to 33.5) | BI 764198 80 mg 38.5 Predicted percentage of patients (95% CI 12.2 to 64.8) vs Placebo 11.4 Predicted percentage of patients (95% CI -2.3 to 25.2)
NCT04176536: Single 40mg dose, matched-pair renal-impairment vs normal-renal-function design (NCT04176536): AUC increased 48% (moderate) / 78% (severe) renal impairment vs healthy controls; Cmax increased 14% / 12%; terminal half-life 12.7-17.4h independent of dose and renal function.
AST-120 (Kremezin)Phase 3Small moleculeOral spherical carbon adsorbentPartial signal
NCT00500682: Primary endpoint, time to composite of dialysis initiation, kidney transplantation or serum creatinine doubling: hazard ratio 1.03 (95% CI 0.84 to 1.27), P=0.78; events AST-120 178/500 vs placebo 177/502. missed
NCT00501046: Primary endpoint, time to composite of dialysis initiation, kidney transplantation or serum creatinine doubling: hazard ratio 0.91 (95% CI 0.74 to 1.12), P=0.37; events AST-120 172/500 vs placebo 183/497. missed
BalcinrenonePhase 3Small moleculeMineralocorticoid receptorPartial signal
NCT04595370: Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline (Day 1) to Week 12): AZD9977 15 mg + Dapagliflozin 10 mg -56.391% (95% CI -71.528--33.207) vs AZD9977 50 mg + Dapagliflozin 10 mg -42.085% (95% CI -64.174--6.376) vs AZD9977 150 mg + Dapagliflozin 10 mg -58.047% (95% CI -73.560--33.430) vs AZD9977 150 mg -45.01% (95% CI NA-NA) vs Dapagliflozin 10 mg -34.318% (95% CI -58.204-3.220) vs Placebo 230.32% (95% CI NA-NA); p=0.3645 (AZD9977 15 mg + Dapagliflozin 10 mg vs AZD9977 50 mg + Dapagliflozin 10 mg vs AZD9977 150 mg + Dapagliflozin 10 mg vs Dapagliflozin 10 mg) missed
Baxdrostat (Baxfendy)Phase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
BHV-1400Phase 3Biologic (subtype unspecified)Gd-IgA1 (galactose-deficient IgA1)not yet gradedNo reviewed efficacy summary in this indication
Bixalomer (Kiklin)Phase 3Small moleculePhosphate binderWeak signal
NCT01742585: Change in serum phosphorus, baseline to end of treatment (12 weeks): bixalomer -0.78 mg/dL (95% CI -0.98, -0.57) vs placebo 0.20 mg/dL (95% CI -0.00, 0.41); mean difference -0.98 mg/dL (95% CI -1.27, -0.69), P < 0.001.
NCT01742611: Mean serum phosphorus: 5.15 mg/dL at baseline, decreasing to 4.67 mg/dL at Week 12, reaching 4.58 mg/dL at Week 48 of open-label bixalomer treatment
Colestilan (Cholebine / BindRen)Phase 3Small moleculePhosphate binderPartial signal
NCT00542815: Primary outcome, change in serum phosphorus from baseline to week 52 in an open-label long-term safety study (no comparator test): -1.23 mg/dL (colestilan from E07/E08), -1.47 mg/dL (colestilan from E07) and -2.26 mg/dL (sevelamer from E07) (CT.gov posted results).
NCT00416520: Serum phosphorus at week 16 (end of the 4-week placebo-controlled withdrawal): 0.43 mmol/L (1.32 mg/dL) lower with colestilan than with placebo (P<0.001) (Locatelli et al., Nephrol Dial Transplant 2014).
Desidustat (Oxemia)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT04215120: Change in hemoglobin baseline to week 16-24: desidustat +0.95 g/dL vs epoetin alfa +0.80 g/dL (difference 0.14 g/dL, 95% CI -0.13 to 0.42), met prespecified noninferiority margin; hemoglobin responders 59.22% desidustat vs 48.37% epoetin alfa (p=0.0382)
NCT04012957: Change in hemoglobin baseline to week 16-24: desidustat +1.95 g/dL vs darbepoetin +1.83 g/dL (difference 0.11 g/dL, 95% CI -0.12 to 0.34), met prespecified noninferiority margin of -0.75 g/dL; hemoglobin responders 77.78% desidustat vs 68.48% darbepoetin (p=0.0181)
ElecoglipronPhase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
EnarodustatPhase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT06016036: Mean Hb change from baseline averaged over Weeks 7-9: enarodustat +15.99 g/L (SD 9.46) vs placebo +0.14 g/L (SD 8.08); P<0.001
NCT04027517: 평가기간 중 투여군간 차이 [95% 신뢰구간] -0.19 [-0.46, 0.08] (이 약 투여군 N=57 평가기간 중 Hb 농도 평균 10.65 g/dL, 다베포에틴 알파 투여군 N=67 10.83 g/dL; 베이스라인 10.73 vs 10.68 g/dL; 비열등성 마진 -1.0 g/dL)
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
HRS-1780Phase 3Small moleculeMineralocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Imlifidase (Idefirix)Phase 3Protein / enzyme therapeuticImmunoglobulin G (IgG), all four human subclassesWeak signal
NCT02790437: Crossmatch conversion (positive to negative) within 24 hours of IdeS dosing: 17 of 19 patients converted; 2 of 19 did not.
Iptacopan (Fabhalta)Phase 3Small moleculeComplement Factor BPartial signal
NCT04578834: Final analysis: annualized total eGFR slope over 24 months, iptacopan -3.10 vs placebo -6.12 mL/min/1.73 m2 per year; difference 3.02 (95% CI 2.02 to 4.01), adjusted P<0.001. Interim (month 9): 24-hour UPCR 38.3% lower with iptacopan (95% CI 26.0 to 48.6), P<0.001. Both primaries met.
NCT03373461: MCP-Mod Estimates of the Ratio to Baseline of Urine Protein to Creatinine Ratio (UPCR) (g/Mol) - Parts 1 and 2 at Day 90 (Baseline and Day 90): LNP023 10 mg BID 0.85 Ratio to baseline (95% CI 0.77-0.93) vs LNP023 50 mg BID 0.80 Ratio to baseline (95% CI 0.73-0.87) vs LNP023 100 mg BID - Part 2 0.76 Ratio to baseline (95% CI 0.70-0.81) vs LNP023 200 mg BID 0.69 Ratio to baseline (95% CI 0.61-0.77) vs Placebo 0.88 Ratio to baseline (95% CI 0.80-1.00); p=0.038 (LNP023 10 mg BID vs LNP023 50 mg BID vs LNP023 100 mg BID - Part 2 vs LNP023 200 mg BID vs Placebo)
JR-131Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signal
NCT02912494: Change in Hb level from baseline to end of treatment (24 weeks): JR-131 −0.42 ± 0.73 g/dL vs darbepoetin alfa −0.43 ± 0.77 g/dL; between-group difference 0.01 g/dL (95% CI −0.19 to 0.20), within the prespecified equivalence margin of −0.5 to 0.5 g/dL
Loncipoetin Alfa (NuPIAO)Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signal
NCT05211167: Reached its pre-set primary endpoint (3SBio 2023 annual report; trial completed January 2024); no figures were given.
MezagitamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
MolidustatPhase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT03543657: Mean Hb during evaluation period (weeks 33-36): molidustat 10.63 g/dL (95% CI 10.42-10.84) vs darbepoetin alfa 10.77 g/dL (95% CI 10.59-10.95); LS mean difference -0.13 g/dL (95% CI -0.46 to 0.19); noninferiority (margin 1.0 g/dL) established
NCT03350347: Mean Hb during the week 30-36 evaluation period: 11.67 g/dL molidustat vs 11.53 g/dL darbepoetin; LS mean difference 0.13 g/dL (95% CI -0.15 to 0.40), inside the 1.0 g/dL noninferiority margin.
MT1013Phase 3PeptideCaSR; OGPPartial signalNo reviewed efficacy summary in this indication
NNG-DEPO (Stimus)Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signalNo reviewed efficacy summary in this indication
Patiromer (Veltassa)Phase 3Small moleculeGastrointestinal potassium binderPartial signal
NCT01810939: Change in Serum Potassium From Part A Baseline to Part A Week 4 (Part A Baseline to Part A Week 4): Part A Patiromer -1.01 mEq/L (Standard Error 0.031)
Pegmolesatide (HS-20039)Phase 3PeptideErythropoietin receptor (EPO-R)Reliable signal
NCT03903809: Mean Hb change from baseline: pegmolesatide +19.2 g/L vs epoetin alfa +15.4 g/L; between-group difference 3.8 g/L (95% CI 0.7-6.9), noninferiority margin -10 g/L
NCT03902691: Mean change in hemoglobin (baseline to evaluation period): +0.07 g/dL pegmolesatide vs -0.22 g/dL epoetin alfa; between-group difference 0.29 g/dL (95% CI 0.11-0.47), non-inferiority verified
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
Rilparencel (Neo-Kidney Augment / REACT)Phase 3Cell therapySelected renal cells (autologous, paracrine)Weak signal
NCT05018416: Primary endpoint (difference in annual eGFR slope, pre- vs post-treatment): Group 1 (n=24) -5.8 to -1.3 mL/min/1.73m2, difference 4.6 per year, 78% improvement, P < .001; Group 2 (n=25) -3.4 to -1.7 mL/min/1.73m2, difference 1.7 per year, 50% improvement, P = .085
Roxadustat (Evrenzo)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Reliable signal
NCT01750190: Mean hemoglobin change over Weeks 28-52: 2.00 g/dL roxadustat vs 0.16 g/dL placebo; least-squares mean difference 1.85 g/dL (95% CI 1.735-1.967; p<0.0001). Hemoglobin response during the first 24 weeks: 523/608 roxadustat vs 20/305 placebo; odds ratio 77.56 (95% CI 44.73-134.48; p<0.0001).
NCT01887600: Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to Hb Response (Baseline to week 24): Roxadustat 79.2% (95% CI 74.8 to 83.1) vs Placebo 9.9% (95% CI 6.1 to 14.8)
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
SC0062Phase 3Small moleculeEndothelin receptor type A (ETA)not yet gradedNo reviewed efficacy summary in this indication
SHR6508Phase 3Small moleculeCalcium-sensing receptor (CaSR)Weak signalNo reviewed efficacy summary in this indication
Sodium Zirconium Cyclosilicate (Lokelma)Phase 3Small moleculeGastrointestinal potassium binderPartial signal
NCT05056727: Total eGFR Slope (Coprimary Analysis #1) (Baseline (Maintenance phase) to visit 17 (week 69)): Maintenance Phase: SZC -5.2975 mL/min/(1.73 m2)/yr (95% CI -6.6854 to -3.9097) vs Maintenance Phase: Placebo -4.5622 mL/min/(1.73 m2)/yr (95% CI -5.9969 to -3.1275) missed
Somatropin (Jintropin)Phase 3Biologic (subtype unspecified)Growth hormone receptorPartial signal
NCT03535415: HT-SDS change at week 52: +0.75 (rhGH-treated) vs +0.17 (untreated control), reported as statistically significant; enrollment (68) and design match NCT03535415 exactly, and the paper is indexed against this NCT.
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)Partial signal
NCT03242018: Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus Placebo (Baseline to Week 26): Sotagliflozin 400 mg -0.4 percentage of HbA1c (Standard Error 0.131) vs Placebo -0.11 percentage of HbA1c (Standard Error 0.151) missed
NCT03242252: Change From Baseline in HbA1c at Week 26 (Baseline to Week 26): Sotagliflozin 200 mg -0.32 percentage of HbA1c (Standard Error 0.06) | Sotagliflozin 400 mg -0.46 percentage of HbA1c (Standard Error 0.06) vs Placebo -0.22 percentage of HbA1c (Standard Error 0.061)
Upacicalcet (UPASITA)Phase 3Small moleculeCalcium-sensing receptor (CaSR)Partial signal
NCT05836220: PATH-2, primary endpoint (iPTH reduction of at least 30%), upacicalcet vs placebo: 43.5% versus 17.4%, for a difference in proportions of 26.1% (95% confidence interval, 17.4 to 34.8, P < 0.001) (J Am Soc Nephrol, 2026-10-23).
NCT05832931: PATH-1, primary endpoint (iPTH reduction of at least 30%), upacicalcet vs placebo: 42.1% versus 16.8%, for a difference in proportions of 25.3% (95% confidence interval, 16.2 to 34.5, P < 0.001) (J Am Soc Nephrol, 2026-10-23).
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)Partial signal
NCT06531824: Discontinued by Boehringer Ingelheim on an independent Data Monitoring Committee recommendation: accumulating data did not support a meaningful expectation of benefit on the primary composite endpoint vs empagliflozin alone (September 2026). missed
NCT05182840: Change in log UACR at week 14 (all patients): 10 mg -0.553 vs placebo -0.066 (difference -0.486, 95% CI -0.660 to -0.313, p<0.0001); 20 mg -0.487 (difference -0.421, 95% CI -0.596 to -0.246, p<0.0001); 3 mg -0.235 (difference -0.168, 95% CI -0.337 to -0.000, p=0.0499). Adjusted median percent change: 10 mg -42.5% vs placebo -6.4%.
Zibotentan + DapagliflozinPhase 3Small moleculeEndothelin A receptor, SGLT2not yet gradedNo reviewed efficacy summary in this indication
ZigakibartPhase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
InaxaplinPhase 2/3Small moleculeAPOL1 (Apolipoprotein L1)Weak signal
NCT06794996: Single-group Phase 2b AMPLIFIED: UACR -42.7% (cohort 1) and -17.3% (AMKD with type 2 diabetes) from baseline at Week 13 (Vertex, 2026-09-22).
NCT04340362: The primary outcome was the percent change from the baseline urinary protein-to-creatinine ratio at week 13 in participants with at least 80% adherence to inaxaplin therapy. Sixteen participants were enrolled; among the 13 who were treated and met the adherence threshold, the mean change from baseline at week 13 was -47.6% (95% confidence interval, -60.0 to -31.3).
KT-301Phase 2/3Microbiome therapeuticProbiotic live biotherapeuticnot yet gradedNo reviewed efficacy summary in this indication
AB002Phase 2Protein / enzyme therapeuticProtein CPartial signal
NCT03963895: Primary outcomes: 40 registered safety and tolerability counts (treatment-related adverse events, access-site bleeding, ECG, anti-thrombin antibodies, vital signs and laboratory changes); safety outcome, no formal efficacy test. Treatment-related TEAEs: 0 in each AB002 dose group and 0 with placebo (CT.gov posted results).
ALN-ANG3Phase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
Avacopan (Tavneos)Phase 2Small moleculeComplement C5a receptor 1 (C5aR1/CD88)Weak signalFeatured results are pharmacokinetic only in this race
CagrilintidePhase 2PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Partial signalNo reviewed efficacy summary in this indication

Large race: only the 60 furthest-along competitors are listed; 39 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Feraheme (Ferumoxytol) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
January 2027 (1)
Phase 2Iron Deficiency AnemiaRecruiting
Est. primary completion 2027-01-30 · NCT05340465 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1Heart Failure With Preserved Ejection Fraction (HFPEF)Recruiting
Est. primary completion 2027-05-31 · NCT07634640 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1Pulmonary Vein StenosisRecruiting
Est. primary completion 2027-06 · NCT06440408 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Central Nervous System Neoplasm, Cranial Nerve Disorder, Metastatic Malignant Neoplasm in the BrainRecruiting
Est. primary completion 2027-12-15 · NCT03270059 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
Phase 1Urinary Bladder NeoplasmsRecruiting
Est. primary completion 2028-01-30 · NCT04369560 · CT.gov ↗
What to watch
October 2028 (1)
Phase 3GlioblastomaRecruiting
Est. primary completion 2028-10-27 · NCT07461948 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 2IDH Wild Type GlioblastomaRecruiting
Est. primary completion 2029-01-31 · NCT03649880 · CT.gov ↗
What to watch
September 2029 (1)
Phase 2Epilepsy, Temporal LobeRecruiting
Est. primary completion 2029-09-01 · NCT06483061 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 October 2025ApprovalFDA approves Ferabright (ferumoxytol injection) for brain MRI
US, FDA · Source ↗